The FDA has approved a groundbreaking new drug to slow the progression of Alzheimer's disease in its early stages, offering ...

The US FDA has authorised a new test ... also facilitate the development of new drug therapies, which are urgently needed as the prevalence of Alzheimer's disease increases with a rapidly ageing ...

The FDA has approved Alnylam’s gene silencing drug Oxlumo ... facility in Ireland that will be used to produce its Alzheimer's therapy donanemab.

Researchers have discovered that Alzheimer's drugs Leqembi and Kisunla boost levels of a healthy form of protein in the brain, even as they reduce its more toxic form.

Two monoclonal antibody treatments to slow Alzheimer's disease, lecanemab (Leqembi) and donanemab (Kisunla), have b ...

If the European Medicines Agency takes an overly cautious approach to selecting specialists to advise on new medicines, ...

Leqembi, an Alzheimer's drug from Biogen and Eisai, faces hurdles with respect to reimbursement and diagnostic uncertainties, diagnostic test requirements and the need for regular brain scans, CNBC ...

Researchers at the Wyss Institute for Biologically Inspired Engineering at Harvard University report that they were able to successfully put tadpoles of Xenopus laevis frogs into a hibernation-like ...

Alzheimer's Drug May Slow Down Cognitive Decline in Dementia With Lewy Bodies Aug. 23, 2024 — Dementia with Lewy bodies is a type of dementia that is similar to both Alzheimer's disease and ...

Alzheimer's Drug May Slow Down Cognitive Decline in Dementia With Lewy Bodies Aug. 23, 2024 — Dementia with Lewy bodies is a type of dementia that is similar to both Alzheimer's disease and ...

The Mini-Mental State Examination (MMSE) continues to be the most widely used screening instrument for Alzheimer's disease (AD). However, the test has been criticized along several lines ...

FDA accepts Biogen's (BIIB) partner Eisai's sBLA for a maintenance intravenous dosing version of Alzheimer's drug Leqembi. The final FDA decision is expected on Jan 25, 2025. Prothena (PRTA ...